Impact of ethnic-specific guidelines for anti-hypertensive prescribing in primary care in England: a longitudinal study

BMC Health Services Research

Christopher Millett³  Marta Blangiardo²  Azeem Majeed³  Utz J Pape³  Craig Leaper³  Lena Barrera¹ 

[1] Department of Primary Care and Public Health, School of Public Health, Imperial College London, Charing Cross Campus, 3rd Floor, Reynolds Building, St Dunstan's Road, London W6 8RP, UK;Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1NY, UK;Department of Primary Care and Public Health, School of Public Health, Imperial College London, London W6 8RP, UK

关键词: Antihypertensive prescribing;    Trend analysis;    Antihypertensive drugs;    Primary care;    Hypertension guidelines;    Hypertension;   

Others  :  1134063
DOI  :  10.1186/1472-6963-14-87

 received in 2013-07-23, accepted in 2014-02-14,  发布年份 2014

【 摘 要 】

Background

In England, the National Institute for Health and Care Excellence (NICE) produces guidelines for the management of hypertension. In 2006, the NICE guidelines introduced an ethnic-age group algorithm based on the 2004 British Hypertension Society guidelines to guide antihypertensive drug prescription.

Methods

A longitudinal retrospective study with 15933 hypertensive patients aged 18 years or over and registered with 28 general practices in Wandsworth, London in 2007 was conducted to assess variations in antihypertensive prescribing. Logistic models were used to measure variations in the odds of being prescribed the 2006 NICE first line recommended monotherapy among NICE patient groups over the period.

Results

From 2000 to 2007, the percentage of patients prescribed the recommended monotherapy increased from 54.2% to 61.4% (p < 0.0001 for annual trend). Over the study period, black patients were more likely to be prescribed the recommended monotherapy than younger non-black patients (OR 0.16, 95% CI 0.12 – 0.21) and older non-black patients (OR 0.49, 95% CI 0.37 – 0.65). After the introduction of the NICE guidelines there was an increase in the NICE recommended monotherapy (OR 1.44, 95% CI 1.19 – 1.75) compared with the underlying trend. Compared to black patients, an increase in the use of recommended monotherapy was observed in younger non-black patients (OR 1.49, 95% CI 1.17 – 1.91) but not in older non-black patients (OR 0.58, 95% CI 0.46 – 0.74).

Conclusion

The introduction of the 2006 NICE guideline had the greatest impact on prescribing for younger non-black patients. Lower associated increases among black patients may be due to their higher levels of recommended prescribing at baseline. The analysis suggests that guidelines did not impact equally on all patient groups.

【 授权许可】

   
2014 Barrera et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Pereira M, Lunet N, Azevedo A, Barros H: Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009, 27(5):963-975.
• [2]Ferrari P: And the National Coordinators for the Reasons for not Intensifying Antihypertensive Treatment (RIAT) trial: Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. J Hum Hypertens 2009, 23(3):151-159.
• [3]Guthrie B, Inkster M, Fahey T: Tackling therapeutic inertia: role of treatment data in quality indicators. BMJ 2007, 335(7619):542-544.
• [4]Natiaonal Institure for Health and Care Excellence: Hypertension: clinical management of primary hypertension in adults (update). (Clinical guideline 127). 2011. Available from: http://guidance.nice.org.uk/CG127 webcite
• [5]Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F: ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013, 34(28):2159-2219.
• [6]Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, on behalf of the American Society of Hypertension Writing Group: Combination therapy in hypertension. J Am Soc Hypertens 2010, 4(2):90-98.
• [7]Tu K, Mamdani MM, Tu JV: Hypertension guidelines in elderly patients: is anybody listening? Am J Med 2002, 113(1):52-58.
• [8]Frisk P, Mellgren TO, Hedberg N, Berlin A, Granath F, Wettermark B: Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines. Eur J Clin Pharmacol 2008, 64(12):1223-1229.
• [9]Frijling BD, Spies TH, Lobo CM, Hulscher ME, van Drenth BB, Braspenning JC, Prins A, van der W, Grol RP: Blood pressure control in treated hypertensive patients: clinical performance of general practitioners. Br J Gen Pract 2001, 51(462):9-14.
• [10]Weiss R, Buckley K, Clifford T: Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 2001-2005. J Clin Hypertens (Greenwich) 2006, 8(10):706-712.
• [11]Hyman DJ, Pavlik VN: Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000, 160(15):2281-2286.
• [12]Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999, 282(15):1458-1465.
• [13]Rochefort CM, Morlec J, Tamblyn RM: What differentiates primary care physicians who predominantly prescribe diuretics for treating mild to moderate hypertension from those who do not? A comparative qualitative study. BMC Fam Pract 2012, 13:9. BioMed Central Full Text
• [14]Fagard RH, Van Den Enden M, Leeman M, Warling X: Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002, 20(7):1297-1302.
• [15]Nicodeme R, Albessard A, Amar J, Chamontin B, Lang T: Poor blood pressure control in general practice: in search of explanations. Arch Cardiovasc Dis 2009, 102(6-7):477-483. [Research Support, Non-U.S. Gov't]
• [16]Hagemeister J, Schneider CA, Barabas S, Schadt R, Wassmer G, Mager G, Pfaff H, Höpp HW: Hypertension guidelines and their limitations–the impact of physicians' compliance as evaluated by guideline awareness. J Hypertens 2001, 19(11):2079-2086.
• [17]Pickering TG: Therapeutic inertia and the Medicare crisis. J Clin Hypertens (Greenwich) 2006, 8(9):667-670.
• [18]Ferrari P, Hess L, Pechere-Bertschi A, Muggli F, Burnier M: Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. J Hypertens 2004, 22(6):1221-1229.
• [19]Johnson DW: Clinicians' attitudes to clinical practice guidelines. Med J Aust 2003, 178(7):354-355. author reply 5; discussion 5-6
• [20]Walker RL, Chen G, Campbell NR, McAlister FA, Quan H, Tu K, Khan NA, Hemmelgarn BR: Canadian provincial trends in antihypertensive drug prescriptions between 1996 and 2006. Can J Cardiol 2011, 27(4):461-467.
• [21]Lester H, Campbell S: Developing Quality and Outcomes Framework (QOF) indicators and the concept of 'QOFability'. Qual Prim Care 2010, 18(2):103-109.
• [22]National Institure for Health and Clinical Excellence: Essential hypertension: managing adult patients in primary care. London; 2004:261. Available from: http://www.nice.org.uk/CG034 webcite
• [23]Wandsworth B: Statistics and census information 2001. Available from: http://www.wandsworth.gov.uk/info/200088/statistics_and_census_information/829/census webcite
• [24]National Collaborating Centre for Chronic Conditions: Hypertension: management in adults in primary care: pharmacological update. London. 2006. Available from: http://www.nice.org.uk/nicemedia/pdf/HypertensionGuide.pdf webcite
• [25]Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom S McG: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004, 18(3):139-185.
• [26]Royston P: PTREND: Stata module for trend analysis for proportions. 2002. Available from: http://ideas.repec.org/c/boc/bocode/s426101.html webcite
• [27]Hanley JA, Negassa A, Edwardes MD, Forrester JE: Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003, 157(4):364-375. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
• [28]Gardiner JC, Luo Z, Roman LA: Fixed effects, random effects and GEE: what are the differences? Stat Med 2009, 28(2):221-239.
• [29]Cui J: QIC program and model selection in GEE analyses. STATA J 2007, 7(2):209-220.
• [30]William R: Regression standard errors in clustered samples. Stata Technical Bulletin Reprints 1993, 13:19-23.
• [31]ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 23, 288:2981-2997.
• [32]Walley T, Duggan AK, Haycox AR, Niziol CJ: Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. J R Soc Med 2003, 96(11):525-531.
• [33]Toschke AM, Gulliford MC, Wolfe CD, Rudd AG, Heuschmann PU: Antihypertensive treatment after first stroke in primary care: results from the General Practitioner Research Database. J Hypertens 2011, 29(1):154-160.
• [34]Schofield P, Baawuah F, Seed PT, Ashworth M: Managing hypertension in general practice: a cross-sectional study of treatment and ethnicity. Br J Gen Pract 2012, 62(603):e703-e709.
• [35]National Instute for Health and Clinical Excellence: NICE implementation uptake report: Hypertension management of hypertension in adults in primary care. 2010.
• [36]Borzecki AM, Glickman ME, Kader B, Berlowitz DR: The effect of age on hypertension control and management. Am J Hypertens 2006, 19(5):520-527.
• [37]Andersen UO, Jensen GB: Trends and determinant factors in hypertension control in a population study with 25 years of follow-up. J Hypertens 2010, 28(5):1091-1096.
• [38]Millett C, Gray J, Bottle A, Majeed A: Ethnic disparities in blood pressure management in patients with hypertension after the introduction of pay for performance. Ann Fam Med 2008, 6(6):490-496.
• [39]Gu Q, Burt VL, Dillon CF, Yoon S: Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012, 126(17):2105-2114.
• [40]Lindholm LH, Carlberg B, Samuelsson O: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366(9496):1545-1553.
• [41]Bangalore S, Parkar S, Grossman E, Messerli FH: A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007, 100(8):1254-1262.
• [42]Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, Herbert C, Milot A, Stone JA, Burgess E, Hemmelgarn B, Jones C, Larochelle P, Ogilvie RI, Houlden R, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Dechamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Tobe S, Touyz RM, Canadian Hypertension Education Program: The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2006, 22(7):583-593.
• [43]Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C, Canadian Hypertension Education Program: The 2004 Canadian recommendations for the management of hypertension: Part II–Therapy. Can J Cardiol 2004, 20(1):41-54.
• [44]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Rocella EJ, and the National High Blood Pressure Education Program Coordinating Committee: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
• [45]Falaschetti E, Chaudhury M, Mindell J, Poulter N: Continued improvement in hypertension management in England: results from the health survey for England 2006. Hypertension 2009, 53(3):480-486.
• [46]Huh D, Flaherty BP, Simoni JM: Optimizing the analysis of adherence interventions using logistic generalized estimating equations. AIDS Behav 2012, 16(2):422-431.